News
BRNS
0.7240
+0.56%
0.0040
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at BRNS last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at BRNS last week (0525-0529)?
Weekly Report · 06/01 10:10
Weekly Report: what happened at BRNS last week (0518-0522)?
Weekly Report · 05/25 10:13
Barinthus Biotherapeutics Shareholders Approve Scheme of Arrangement
TipRanks · 05/21 10:36
Weekly Report: what happened at BRNS last week (0511-0515)?
Weekly Report · 05/18 10:13
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Barchart · 05/11 11:08
Weekly Report: what happened at BRNS last week (0504-0508)?
Weekly Report · 05/11 10:10
Weekly Report: what happened at BRNS last week (0427-0501)?
Weekly Report · 05/04 10:08
Barinthus Biotherapeutics GAAP EPS of -$0.14
Seeking Alpha · 05/01 12:51
Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability
TipRanks · 05/01 06:00
Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
TipRanks · 04/30 16:30
Barinthus Biotherapeutics Q1 EPS $(0.14) Beats $(0.30) Estimate
Benzinga · 04/30 11:59
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/30 09:26
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Barchart · 04/30 06:30
Weekly Report: what happened at BRNS last week (0420-0424)?
Weekly Report · 04/27 10:11
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
TipRanks · 04/22 21:35
Weekly Report: what happened at BRNS last week (0413-0417)?
Weekly Report · 04/20 10:07
Weekly Report: what happened at BRNS last week (0406-0410)?
Weekly Report · 04/13 10:10
Weekly Report: what happened at BRNS last week (0330-0403)?
Weekly Report · 04/06 10:11
More
Webull provides a variety of real-time BRNS stock news. You can receive the latest news about Barinthus Biotherapeutics plc through multiple platforms. This information may help you make smarter investment decisions.
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.